Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Sells $4,971,637.20 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Mayukh Sukhatme sold 412,584 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the transaction, the executive now owns 18,836,547 shares in the company, valued at $226,980,391.35. The trade was a 2.14 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Roivant Sciences Stock Up 0.6 %

Shares of NASDAQ ROIV traded up $0.07 during midday trading on Friday, reaching $11.57. 15,754,118 shares of the stock were exchanged, compared to its average volume of 5,795,466. The firm has a market cap of $8.42 billion, a price-to-earnings ratio of 2.05 and a beta of 1.25. The firm has a 50-day simple moving average of $11.91 and a two-hundred day simple moving average of $11.48. Roivant Sciences Ltd. has a twelve month low of $9.69 and a twelve month high of $13.06.

Wall Street Analyst Weigh In

ROIV has been the topic of several research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. Finally, Bank of America lifted their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.93.

Institutional Trading of Roivant Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Retirement Systems of Alabama grew its stake in Roivant Sciences by 26.9% in the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after acquiring an additional 112,286 shares during the period. Tyro Capital Management LLC grew its position in shares of Roivant Sciences by 0.6% in the third quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company’s stock valued at $20,252,000 after purchasing an additional 10,649 shares during the period. Te Ahumairangi Investment Management Ltd increased its stake in shares of Roivant Sciences by 19.9% during the third quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company’s stock worth $2,313,000 after purchasing an additional 33,467 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Roivant Sciences during the 3rd quarter worth about $207,000. Finally, Geode Capital Management LLC lifted its stake in Roivant Sciences by 23.2% in the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock valued at $89,400,000 after buying an additional 1,460,205 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.